E.i. Dupont De Nemours and Company

Abbvie Biotechnology Ltd

Other

L'air Liquide, S.a.

Mark Weinberg

Rebecca S Hoffman

Elliot Keith Chartash

George Richard Granneman

Lori K Taylor

Philip Yan

Jochen G Salfeld

Edmund Arthur Flexman

Steven Alan Fischkoff

Subhashis Banerjee

Bryan Benedict Sauer

Daniel Edward Tracey

Anwar Murtaza

William T Barchuk

Clive E Spiegler

Ronald James McKinney

Edward George Howard, Jr

Ralph Birchard Lloyd

Rudolf H Scheffrahn

Steven S Adkinson

Avi Fattal

Jose Manuel Rodriguez-Parada

Gregory T Dee

Sabine Gabriel

Lakshmi Krishnamurthy

Mieczyslaw (Michel) Stachnik

Nathaniel A Barney

The invention describes methods of treating erosive polyarthritis comprising administering a TNF&#x3b1; antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF&#x3b1; antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Use of TNF&#x3b1; inhibitor

Use of TNF&#x3b1; inhibitor for treatment of psoriasis

Use of TNF&#x3b1; inhibitor for treatment of psoriatic arthritis

Chitosan films and laminates made from the films are provided. The films and laminates can be used to make a variety of finished articles that can be used to provide protection from hazardous chemical and biological agents.

Laminates of chitosan films

Use of TNF-alpha inhibitor for treatment of psoriasis

The present invention relates to a flame retardant plexifilamentary film-fibril strand comprising at least one polyolefin and at least one flame retardant selected from the group consisting of: phosphate esters, phosphonate esters, phosphinate esters, polyphosphazines, nitrogen-containing polyphosphates, hindered amines and mixtures thereof. The present invention also relates to flame retardant sheet made from the flame retardant plexifilamentary film-fibril strands. The sheet can be made into a flame retardant building substrate, garment, banner, light reflector and cover.

Flame retardant flash spun sheets

Use of TNF alpha inhibitor for treatment of erosive polyarthritis

Use of human TNF&#x3b1; antibodies for treatment of erosive polyarthritis

Inclusion of a needle structured sepiolite clay in a chitosan film in an amount of about 0.5 weight percent to about 8 weight percent was found to reduce shrinkage of the film. The clay is processed into a substantially dispersed form. Laminates fabricated from this chitosan film including dispersed sepiolite clay can be used in making a variety of finished articles that can be used to provide protection from hazardous chemical and biological agents.

Chitosan films with reduced shrinkage and laminates made therefrom

Processes for fabricating selectively permeable laminates are provided. In one process, continuous chitosan film is prepared by casting a chitosan solution directly onto a substrate that will be incorporated along with the film into a laminate. Alternatively, the chitosan solution is cast onto a work device (for example, such as glass or a polymer film), dried, detached, and then incorporated into a laminate in a separate step. In various embodiments, the laminates are useful for fabrication as a protective article and are substantially impermeable to hazardous chemical and biological agents, but sufficiently permeable to water vapor that, if worn as protective apparel, it is both protective and comfortable to wear.

Processes for making selectively permeable laminates

The present invention is concerned with flash-spinning a surface-modified structure such as a plexifilimentary yarn or a microcellular foam.

Surface-modified plexifilamentary structures, and compositions therefor

Liquid crystalline polymers (LCP) with relatively high melting points are prepared by a process which includes solid state polymerization of a (pre)polymer, which contains alkali metal cations, to raise the LCP molecular weight. The presence of the alkali metal cations in the (pre)polymer usually results in a final polymer with less color and/or a higher melting point. The LCPs are useful as molding resins and for films.

Compatibility improvement in aromatic polyesters with mineral fillers

A method of decontaminating a structure contaminated by pathogenic microorganisms such asand its spores,varand its spores, andand its spores. The steps include sealing a contaminated structure sufficiently to enable retention of a gas, introducing methyl bromide gas into sealed contaminated structure to a concentration of methyl bromide in an amount sufficient to deactivate said pathogenic microorganisms and to disable germination of pathogenic bacteria spores, and maintaining said sealed contaminated structure with said concentration of methyl bromide at a sufficient temperature for a sufficient period of time, and deactivating said pathogenic microorganisms and disabling germination of said pathogenic bacteria spores associated with said contaminated structure. The method is performed approximately in the range of 20&#xb0; C. to 40&#xb0; C., and the concentration of methyl bromide is about 80 mg/l to 303 mg/l during the decontamination. Humidity is not a factor in the efficacy of this treatment process.

Method of decontamination of whole structures and articles contaminated by pathogenic spores

Growing community of inventors

Northbrook, IL, United States of America

Mark Weinberg